Healthcare is one of the largest and fastest-evolving sectors in the world, with global spending expected to keep rising as populations age and new treatments emerge.
Within the industry, companies that can sustain 10%+ revenue growth are rare, and they often share a few key traits.
They typically own differentiated therapies or technologies, benefit from strong demand tailwinds, and operate with business models that scale as they expand.
Consistent double-digit growth in healthcare not only signals strong execution but also positions these companies to reinvest in innovation, expand into new markets, and strengthen their competitive edge. For investors, these are the kinds of businesses that can deliver compounding returns while tapping into some of the most durable trends in the global economy.
Here are the 10 healthcare stocks that have delivered consistent 10%+ revenue growth, highlighting the operators best positioned to keep scaling in the years ahead.
| Company Name (Ticker) | Analyst Upside | P/E Ratio |
| Eli Lilly and Company (LLY) | 21.3% | 26.42 |
| Novo Nordisk A/S (NVO) | 12.9% | 14.09 |
| DexCom (DXCM) | 35.5% | 31.95 |
| Insulet Corporation (PODD) | 4.0% | 67.96 |
| Intuitive Surgical (ISRG) | 23.0% | 55.26 |
| Inspire Medical Systems (INSP) | 53.9% | 103.44 |
| Exact Sciences Corporation (EXAS) | 32.8% | 66.41 |
| Moderna (MRNA) | 88.7% | -2.39 |
| Align Technology (ALGN) | 31.3% | 13.45 |
| Guardant Health (GH) | -9% | -36.95 |
Unlock our Free Report: 5 undervalued compounders with upside based on Wall Street’s growth estimates that could deliver market-beating returns (Sign up for TIKR, it’s free) >>>
Here are 3 stocks that could be most undervalued today:
Eli Lilly (LLY)
Eli Lilly has become one of the most reliable growth engines in the healthcare sector, with revenues compounding at well above 20% annually in recent years. The key driver has been its leadership in the GLP-1 space through blockbuster drugs like Mounjaro and Zepbound, which are transforming the treatment landscape for diabetes and obesity. These therapies are seeing explosive adoption globally, with obesity care emerging as one of the largest pharmaceutical opportunities in decades. Lilly has also invested heavily in expanding manufacturing capacity to meet surging demand, ensuring its revenue trajectory remains steep.
Beyond its GLP-1 portfolio, Lilly’s growth is supported by diversification across other therapeutic areas, including neuroscience, immunology, and oncology. The launch of Donanemab for Alzheimer’s disease, pending regulatory approval, could open a multi-billion-dollar revenue stream in an underserved space.
Find stocks that we like even better than Eli Lilly today with TIKR (It’s free) >>>
DexCom (DXCM)
Dexcom has consistently delivered double-digit top-line growth, cementing its status as a leader in diabetes management technology. The company’s flagship continuous glucose monitoring (CGM) devices have transformed patient care by reducing the need for fingerstick testing and enabling real-time, data-driven disease management. As payers expand coverage and adoption broadens from Type 1 to Type 2 diabetes patients, Dexcom is tapping into a significantly larger addressable market, sustaining annual revenue growth in the 15–20% range.
Importantly, Dexcom’s growth story is not only about expanding its user base but also about increasing patient retention and device innovation. The launch of Dexcom G7 has been met with strong demand, offering enhanced accuracy and convenience. International expansion is accelerating as well, with Europe and emerging markets contributing more meaningfully to revenue. With the diabetes population rising globally and greater emphasis on digital health, Dexcom is uniquely positioned to maintain consistent double-digit revenue growth well into the future.
Value stocks like Dexcom quicker with TIKR >>>
Insulet Corporation (PODD)
Insulet, the maker of the Omnipod insulin delivery system, represents one of the most compelling med-tech growth stories of the past decade. Unlike traditional tubed insulin pumps, the Omnipod’s patch-based design offers a simpler, more discreet, and user-friendly experience, driving rapid adoption among both Type 1 and Type 2 diabetes patients. This innovation has helped Insulet deliver revenue growth of 15–20%+ annually, supported by strong U.S. penetration and a growing international footprint.
A critical factor in Insulet’s consistent growth is its expanding payer coverage, which lowers barriers to adoption and broadens its customer base. Recent launches like Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, are deepening Insulet’s competitive moat and keeping it at the forefront of diabetes tech innovation. With diabetes prevalence increasing worldwide, Insulet’s combination of product differentiation, strong recurring revenue from supplies, and international expansion ensures it remains firmly in the 10%+ growth category.
Value any stock in under 30 seconds with TIKR’s new Valuation Model (it’s free) >>>
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
